Cell proliferation reducing cancer specific PCNA peptides
AssigneeIndiana University Research and Technology Corporation
InventorsLinda H. Malkas, Robert J. Hickey
Life of this patent
Estimating the term…
Abstract
Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics.
Claims16
A therapeutic composition for reducing cellular proliferation of malignant cells, the composition comprising a peptide molecule fused or linked to a cell penetrating peptide, wherein the peptide molecule comprises an amino acid sequence selected from the group consisting of LGIPEQEY (SEQ ID NO:
- 1), LAIPEQEY (SEQ ID NO:
- 2), LGIAEQEY (SEQ ID NO:
- 3), LGIPAQEY (SEQ ID NO:
- 4), LGIPEAEY (SEQ ID NO:
- 5), LGIPEQAY (SEQ ID NO:
- 6), LGIAEAEY (SEQ ID NO:
- 7), LGIPEAAY (SEQ ID NO:
- 8), LGIAEQAY (SEQ ID NO:
- 9), and LGIAEAAY (SEQ ID NO:
- 10), and wherein the cell penetrating peptide comprises an amino acid sequence selected from the group consisting of RRRRRRR (SEQ ID NO:
- 11), RRRRRRRR (SEQ ID NO:
- 12), RRRRRRRRR (SEQ ID NO:
- 13), RRRRRRRRRR (SEQ ID NO:
- 14), RRRRRRRRRRR (SEQ ID NO:
- 15), RQIKIWFQNRRMKWKK (SEQ ID NO:
- 16), GRKKRRQRRRPPQ (SEQ ID NO:
- 17), GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:
- 18), and GRKKRRQRRR (SEQ ID NO:
- 19).
A method In vitro of reducing cellular proliferation or inducing cell death of a cancer cell or a pre-malignant cell expressing cancer-specific proliferating cell nuclear antigen (caPCNA), the method comprising administering a therapeutically effective amount of a composition comprising a peptide molecule fused or linked to a cell penetrating peptide, wherein the peptide molecule comprises an amino acid sequence selected from LGIPEQEY (SEQ ID NO:
- 1), LAIPEQEY (SEQ ID NO:
- 2), LGIAEQEY (SEQ ID NO:
- 3), LGIPAQEY (SEQ ID NO:
- 4), LGIPEAEY (SEQ ID NO:
- 5), LGIPEQAY (SEQ ID NO:
- 6), LGIAEAEY (SEQ ID NO:
- 7), LGIPEAAY (SEQ ID NO:
- 8), LGIAEQAY (SEQ ID NO:
- 9), and LGIAEAAY (SEQ ID NO:
- 10), and wherein the cell penetrating peptide comprises an amino acid sequence selected from the group consisting of RRRRRRR (SEQ ID NO:
- 11), RRRRRRRR (SEQ ID NO:
- 12), RRRRRRRRR (SEQ ID NO:
- 13), RRRRRRRRRR (SEQ ID NO:
- 14), RRRRRRRRRRR (SEQ ID NO:
- 15), RQIKIWFQNRRMKWKK (SEQ ID NO:
- 16), GRKKRRQRRRPPQ (SEQ ID NO:
- 17), GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:
- 18), and GRKKRRQRRR (SEQ ID NO:
- 19), to contact the cancer or pre-malignant cell expressing caPCNA.
Dependencies are inferred from the claim text.